Compare
Siga Technologies Inc vs Standard Biotools Inc. vs UroGen Pharma Ltd. vs ADC Therapeutics SA
| Latest fiscal year | Siga Technologies Inc SIGA | Standard Biotools Inc. LAB | UroGen Pharma Ltd. URGN | ADC Therapeutics SA ADCT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $94.57M | $85.33M | $109.79M | $81.36M |
| Revenue growth (YoY) | -31.8% | -6.2% | +21.4% | +14.9% |
| Gross margin | 68.6% (computed) | 49.9% | 88.7% | 92.9% (computed) |
| Operating margin | 25.1% | -129.2% | -113.7% | -149.3% |
| Net margin | 24.6% | -87.8% | -139.8% | -175.3% |
| Net income | $23.28M | -$74.90M | -$153.49M | -$142.62M |
| EPS (Diluted) | $0.32 | -$0.20 | n/a | -$1.12 |
| Operating cash flow | $43.47M | -$74.34M | -$162.44M | -$141.17M |
| Free cash flow | n/a | -$82.65M | -$162.73M | -$141.44M |
| Cash & equivalents | $154.97M | $120.86M | $110.75M | $261.34M |
| Total assets | $219.47M | $567.75M | $200.46M | $323.15M |
| Total liabilities | $20.65M | $143.46M | $305.93M | $508.98M |
| Shareholders' equity | $198.82M | $424.29M | -$105.47M | -$185.83M |
| Return on year-end equity | 11.7% | -17.7% | n/a | n/a |
| Shares outstanding | 71.61M | 386.38M | 48.35M | 125.75M |
Revenue, most recent five fiscal years
| Fiscal year | Siga Technologies Inc | Standard Biotools Inc. | UroGen Pharma Ltd. | ADC Therapeutics SA |
|---|---|---|---|---|
| Latest | $94.57M Ended 2025-12-31 | $85.33M Ended 2025-12-31 | $109.79M Ended 2025-12-31 | $81.36M Ended 2025-12-31 |
| 1 year earlier | $138.72M Ended 2024-12-31 | $91.01M Ended 2024-12-31 | $90.40M Ended 2024-12-31 | $70.84M Ended 2024-12-31 |
| 2 years earlier | $139.92M Ended 2023-12-31 | $106.34M Ended 2023-12-31 | $82.71M Ended 2023-12-31 | $69.56M Ended 2023-12-31 |
| 3 years earlier | $110.78M Ended 2022-12-31 | $97.95M Ended 2022-12-31 | $64.36M Ended 2022-12-31 | $209.91M Ended 2022-12-31 |
| 4 years earlier | $133.67M Ended 2021-12-31 | $130.58M Ended 2021-12-31 | $48.04M Ended 2021-12-31 | n/a |